Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / Apr / Ready, Steady, Propel!
Discovery & Development Drug Delivery

Ready, Steady, Propel!

Can micromotors give oral vaccine technology the boost it needs?

By Maryam Mahdi 04/16/2019 0 min read Quick Read (pre 2022)

Share

Convenient, cost-effective and with high rates of patient compliance, the oral route has and will continue to be one of the most popular options for drug delivery, but for vaccines the oral route has proven challenging. Although some oral vaccines can stimulate immune cells in mucus layer of the intestine to produce IgA (a class of antibody), for the most part the insufficient potency of oral vaccines has prevented them from conferring ample protection against pathogens. In an effort to overcome these limitations, researchers at the University of San Diego have developed oral vaccines with a twist - they are powered by micromotors to target the mucus layer of the intestine (1). 

“We hypothesized that by using micromotor technology to add active propulsion to oral vaccines, we could facilitate enhanced processing of vaccines by the immune system. This would, in turn, would generate a much stronger immune response (in the form of higher antibody levels) compared with formulations that lack propulsion,” explains Ronnie Fang, Assistant Project Scientist in the Department of NanoEngineering at UC San Diego.

The motor vaccine formulation developed by the  La Jolla based team consists of several components, but at the heart of the drug is a magnesium core coated in titanium dioxide used to propel the vaccine.

“The titanium coating on the core is placed asymmetrically allowing one side of the magnesium core to be exposed to interact with the biological fluids that power the motors,” explains Fang. “The motor core is then coated with a layer of red blood cell membrane to help cue the immune system and allow it to illicit appropriate responses.”

To allow the motor cores to adhere to the intestinal wall lining and protect them from succumbing to the harsh environment of the stomach, the researchers added additional chitosan and enteric polymer layers to coat their molecules. The team were able to successfully feed their formulation to mice and found that the propulsion mechanism they had devised enabled better retention of the vaccine material on the intestine wall and greater amounts of antibody when compared to  static microparticles.  

The positive results have encouraged the team to move their work beyond a proof-of-concept. They believe that the concept of motor-based vaccines should be able to apply to any type of infectious disease, once its safety in humans has been tested. 
 

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Liangfang Zhang et al., “Biomimetic Micromotor Enables Active Delivery of Antigens for Oral Vaccination”, Nano Lett. 1914-1921 (2019).

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Managing Change in Devices for Patients
Drug Delivery
Managing Change in Devices for Patients

June 21, 2024

4 min read

We need to step away from assumptions on device interchangeability and find out what patients really want

Dosing to Circadian Rhythm
Drug Delivery
Dosing to Circadian Rhythm

December 1, 2014

0 min read

Could medicines be made more effective with better timing?

Connecting the Dots in Drug Delivery
Drug Delivery
Connecting the Dots in Drug Delivery

December 1, 2014

0 min read

The days of “low-hanging fruit” in drug discovery are a thing of the past...

Squid-Inspired Drug Delivery
Drug Delivery Dosage Forms Formulation
Squid-Inspired Drug Delivery

April 3, 2025

4 min read

Here’s how researchers took lessons from cephalopods to develop a new capsule that can deliver drugs, including insulin and siRNA, orally

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.